STALE?Report written 7 days ago · at $0.94entry levels may be stale — re-check before acting

IVVD

ค่าขนมSMALL CAP

Invivyd, Inc. · NASDAQ · Healthcare / Biotechnology — Infectious Disease / Antibody Therapeutics

$0.94

▼ 3.00%

MCap $162M (Sep 27, 2026)

Down ~66% YTD and ~13% this month after a Q2 EPS/revenue miss on Sep 22 — trading near the bottom of a $0.53-$3.05 52-week range just as the pivotal DECLARATION readout (guided 'late Q3 2026') comes due

BusinessAntibody therapeutics · VYD2311 — next-gen long-acting monoclonal antibody for COVID-19 prevention in immunocompromised patients; pivotal Phase 3 readout imminent

Thesis

Invivyd's entire near-term thesis rides on DECLARATION, the Phase 3 pivotal trial for VYD2311 (a next-gen, longer-acting successor to its commercial antibody PEMGARDA) — enrollment completed in June 2026 and topline data is guided for approximately late Q3 2026, i.e. within days of today. The stock has been crushed heading into the readout: -66% YTD, with an 8% single-day drop on Sep 22 after a Q2 EPS/revenue miss, leaving almost no cushion if the trial disappoints. Cash of $160.1M (Q2 2026) is explicitly guided to cover through the DECLARATION readout and initial commercial launch readiness, so this is a binary data bet, not a survival one — but the beaten-down legacy franchise and imminent timing mean there's little room for error.

📝 Primary Verdict · Core Holding

SPECULATIVEค่าขนม

SPECULATIVE — ค่าขนม only, cap at 2% of portfolio (low end of the 2-5% band). The measured median at-catalyst return across turbo picks is -13.7% (n=19), which argues against chasing $0.94 — BUT DECLARATION is guided for 'late Q3 2026' (ends Sep 30, today's date), so there may be no practical dip window before the readout; size down at Entry 1 if the dip zone never prints, rather than forcing it. fda_decision is turbo's best-performing catalyst type on record (+9.3pp median excess, n=10), but IVVD carries extra red flags a clean fda_decision pick wouldn't: a Q2 earnings miss, a declining/variant-pressured legacy franchise, and a stock already down ~66% YTD.

82

score / 100 ⓘ

⚡ Catalyst

🧪 DECLARATION Phase 3 topline (VYD2311)DAYS AWAY

Pivotal Phase 3 topline data for VYD2311, a next-gen long-acting monoclonal antibody for COVID-19 prevention in immunocompromised patients — guided for approximately late Q3 2026; the LIBERTY trial topline may read out alongside it. This is a trial readout that determines the BLA path, not a PDUFA date itself.

~Early Oct 2026

🎯 Entry Point

Entry 1

$0.94

Current price — DECLARATION topline is guided for 'late Q3 2026' (which ends Sep 30), so there is almost no time buffer to wait for a dip before the binary eventNow

Entry 2PREFERRED

$0.75–0.85

Dip zone — continued post-Q2-miss drift; the measured turbo entry edge favors this over chasing $0.94, though it may not print before dataIf dips (may not arrive before data)

Entry 3

$0.55

Deep dip — at the 52-week low ($0.53); only on further pre-data selling or a broad biotech risk-off moveDeep dip only

✅ Take Profit

TP1

Base — DECLARATION hits its primary endpoint with a solid effect size, de-risking the BLA path; a re-rate off penny-stock levels within roughly 4-8 weeks of the readout as institutional interest returns

$2.35

+150%

TP2

Bull — strong efficacy signal plus a clean LIBERTY readout too, re-rating back above the 52-week high ($3.05)

$3.76

+300%

TP3 🌙

Moon — clean pivotal win plus a clear BLA-acceptance track plus M&A interest (the new CEO's pay package is explicitly tied to a $5B+ sale outcome)

$6.11

+550%

🔴 Stop Loss

Tight Stop

Wider than the fda_decision turbo-lane medianMAE of -18.4% (n=10) — appropriate given this is a sub-$1 stock already down ~66% YTD heading into a days-away binary event

$0.66

-30%

Hard Stop

Below the 52-week low ($0.53) — would confirm the market is pricing a DECLARATION miss or a deeper franchise problem

$0.42

-55%

Risk / Reward

Tight stop (-30%) vs TP2/Bull (+300%)

10 : 1

⚠ Asymmetric ✅ — clears the turbo ≥5:1 target, but this is a sub-$1 microcap; cents matter more than percentages here

📅 Estimate Date

DECLARATION Phase 3 topline (VYD2311)

Guided 'approximately late Q3 2026' as of the Jun 2026 enrollment-completion release; LIBERTY topline may accompany it

~Late Sep – Oct 2026

Primary endpoint hit / miss

Potential BLA submission (if DECLARATION positive)

No formal FDA filing timeline guided yet — contingent entirely on the DECLARATION readout

H1 2027 (est.)

n/a

📈 Possible Up % — Scenario Spread

Bear

-65%

$0.33

Base

+150%

$2.35

Bull

+300%

$3.76

Moon

+550%

$6.11

← downsideupside →

🏛️ Fed / Macro Risk — LOW

Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution

Rate Outlook

Same easing-bias backdrop as the broader market (the Aug 2026 payrolls miss pushed rate-hike odds lower) — largely irrelevant to whether DECLARATION hits its primary endpoint.

Inflation

Core PCE at 3.3% YoY (Jun 2026 print) is a macro tail risk for risk assets broadly, but IVVD is currently trading almost entirely on its own binary catalyst and its Q2 earnings miss, not on macro inputs.

Sector Impact

A risk-off macro shock would amplify any post-DECLARATION-miss drawdown and could pressure the company's ability to raise capital later if the trial disappoints, given IVVD is already a distressed-looking micro-cap.

Summary

Fed risk is LOW for the thesis itself — this trades on DECLARATION, not on rates. Macro matters here as a volatility amplifier around the event, not as a driver of the outcome.

🎯 Analyst Targets

Wall Street price targets vs the current price — cross-check our TP levels

Wall Street Consensus (6 analysts, post-Q2 miss)

Hold$8+751%

Wall Street Consensus (9 analysts, pre-Q2 print)

Strong Buy$10.2+985%

current price $0.94

🔍 Similar-Catalyst Comparable Check

Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic

KOD✅ GoodSep 2026

+172%

in 1 day

Phase 3 DAYBREAK topline win (Zenkuda/tarcocimab, wet AMD)

Small-cap biotech, positive pivotal Phase 3 topline just weeks before IVVD's own readout — direct evidence binary Phase 3 wins still produce 150%+ single-day moves in this market regime (reported as +166% to +180% depending on the intraday mark).

EYPT❌ BadAug 2026

-71%

in 1 day

Phase 3 LUGANO primary endpoint miss (Duravyu vs. Eylea, wet AMD)

Small-cap biotech binary Phase 3 miss just one month before IVVD's own DECLARATION readout — the direct downside precedent for this exact type of imminent single-catalyst risk.

CAPR✅ GoodDec 2025

+300%

in 2 days

Phase 3 HOPE-3 data win (deramiocel, DMD)

Cross-sector but the same catalyst mechanism (binary Phase 3 topline in a beaten-down small-cap) — shows the tail-upside case for IVVD isn't fabricated, even if IVVD's own commercial overhang argues for a more moderate base case.

⚡ Optional Layer · Tactical Overlay

🎯 Catalyst Spot Mode

Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.

⚠️

Use this stop-loss set (-30% / -55%) only when trading the earnings spot — not for the core holding (use the -30% / -55% set above). If you are holding long-term, follow the core set.

📈Pre-Catalyst Run-up Pattern

-10% to +15% (choppy, no clean pattern for this name specifically)1-2 สัปดาห์ก่อน readout

Sub-$1 binary-catalyst biotechs often see thin, choppy pre-event trading with occasional speculative pops on positioning rather than a reliable directional drift — IVVD's own price action into the DECLARATION window has actually been more downdrift (post-Q2-earnings-miss selling) than run-up so far.

🎲Historical Post-Catalyst Move

✅ Catalyst Winavg +175%

range: +166% to +300%· Sep 2026

Kodiak Sciences (KOD) jumped ~166-180% on its Sep 28, 2026 Phase 3 DAYBREAK topline win in wet AMD — a small-cap biotech binary Phase 3 win just weeks before IVVD's own readout, direct evidence 150%+ single-day moves still happen in this regime. Capricor's own +300% Dec 2025 Phase 3 win is a further (cross-sector) tail-upside reference, though IVVD's Q2 earnings-miss overhang argues for a more moderate outcome than either.

❌ Catalyst Missavg -71%

range: -55% to -71%· Aug 2026

EyePoint Pharmaceuticals (EYPT) fell 71% in one day on Aug 17, 2026 when its Phase 3 LUGANO trial missed its primary endpoint in wet AMD — a small-cap biotech binary Phase 3 miss just one month before IVVD's own DECLARATION readout, the direct downside precedent for this exact type of imminent single-catalyst risk.

💼Spot Position Sizing

How the recommended % is derived

2%

of portfolio

Smallest end of the 2-5% ค่าขนม band — DECLARATION is one of the strongest single-catalyst setups in the turbo lane by type (fda_decision), but the Q2 earnings miss, prior variant-escape efficacy concerns on the legacy franchise, and days-away binary timing (little room to average in beforehand) argue for capping size low.

🛑Stop Loss · Spot Trade

Spot cut-loss levels — separate from the core holding

Before Catalyst

-30%($0.66)

Thesis breach if IVVD breaks toward the 52-week low before data without news — would suggest the market is pricing a miss.

After Catalyst (Bad Result)-55%

If DECLARATION misses the primary endpoint, exit — PEMGARDA's declining, variant-pressured legacy franchise alone doesn't support the current valuation without a VYD2311 Phase 3 win.

📎 Sources

https://investors.invivyd.com/news-releases/news-release-details/invivyd-reports-second-quarter-2026-financial-results-and-recent https://www.globenewswire.com/news-release/2026/06/01/3304208/0/en/invivyd-announces-completion-of-enrollment-in-upsized-declaration-clinical-trial-a-phase-3-pivotal-study-of-vyd2311-an-investigational-antibody-to-prevent-covid.html https://www.stocktitan.net/news/IVVD/invivyd-appoints-chairman-marc-w-elia-as-chief-executive-officer-j2bd4mqtttct.html https://www.biospace.com/drug-development/eyepoints-phase-3-fail-sends-stock-spiraling-amid-next-gen-amd-race https://www.biospace.com/drug-development/kodiak-sciences-stock-soars-166-after-2-assets-match-eylea-in-phase-3-trial https://www.aaii.com/investingideas/article/484967-why-invivyd-inc8217s-ivvd-stock-is-down-574 https://www.wallstreetzen.com/stocks/us/nasdaq/ivvd/stock-forecast

Generated 2026-09-29 · Not financial advice